Free Trial

NovAccess Global 2/27/2024 Earnings Report

NovAccess Global logo
$0.0003 0.00 (0.00%)
As of 04/8/2025

NovAccess Global EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NovAccess Global Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NovAccess Global Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Remove Ads

CSX Earnings Headlines

CSX (NASDAQ:CSX) Price Target Lowered to $36.00 at Citigroup
CSX (CSX) Projected to Post Quarterly Earnings on Wednesday
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
CSX price target lowered to $36 from $39 at Citi
J.P. Morgan Sticks to Its Buy Rating for CSX (CSX)
See More CSX Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovAccess Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovAccess Global and other key companies, straight to your email.

About NovAccess Global

NovAccess Global (OTCMKTS:XSNX), a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

View NovAccess Global Profile

More Earnings Resources from MarketBeat